AimwellBio Releases Detailed Investor Briefing on $10 Million Trustr IP Portfolio Acquisition

Aimwell Partners Inc. (OTC:AIMN), operating as AimwellBio, announced on August 13, 2026, the release of a comprehensive investor briefing regarding its recent acquisition of the Trustr intellectual property portfolio. This briefing is made available to current and prospective investors to provide documented visibility into the assets, technology, and intellectual property underpinning the company’s growth strategy.

The Trustr portfolio centers on a U.S. patent family that covers systems designed to measure real-world behavior against personalized performance indicators. It delivers precisely timed reward and loss-aversion messaging aimed at supporting sustained behavioral change.

Originally licensed through the University of Vermont Office of Technology and Commercialization, the technology has a documented institutional lineage involving Oxford University, the University of Vermont, Cornell University, the Academy of Managed Care Pharmacy (AMCP), and a pilot program with Sanofi targeting moderate-to-severe asthma patients.

The technology was examined by the Cornell Consulting Group as early as 2015 and received a Gold Ribbon award at AMCP 2020. Within AimwellBio, it is expected to serve as a behavioral engagement and real-world evidence layer supporting applications across medication adherence, remote patient monitoring, clinical trial retention, and patient-reported outcomes.

The investor briefing provides a detailed review of the patent filings, platform architecture, development history, and the individuals and institutions associated with the technology. It also identifies outstanding diligence items that remain under review or confirmation.

John Morgan, Principal of AimwellBio, emphasized the company’s commitment to transparency: "Anyone can tell investors they have intellectual property. We would rather provide the record—the filings, the institutions, the people, the history, and the questions we are still working to close out. Investors should be able to see what is tangible and understand exactly what we are building from."

Dr. Chris A. Jones, D.Phil. (Oxford), the portfolio’s inventor and a behavioral economist whose doctoral work received the Bertarelli Prize, has joined AimwellBio’s Board of Advisors. He is leading efforts to expand the platform through the introduction and evaluation of additional intellectual property, technologies, assets, and experienced operators.

Dr. Jones stated, "Trustr was built to influence what patients actually do between visits, which is often where healthcare outcomes are won or lost. AimwellBio provides an opportunity to expand that technology into a broader platform. Trustr is the beginning of what I intend to bring to the AimwellBio ecosystem in terms of intellectual property, assets, and people."

Current and prospective investors may request access to the full confidential investor briefing through AimwellBio Investor Relations.

AimwellBio is a biopharma intelligence platform integrating patented behavioral engagement technology, real-world evidence capture, and clinical-grade analytics designed to improve patient engagement, adherence, and outcomes while providing actionable intelligence across the healthcare ecosystem.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Aimwell Partners Inc.’s business strategy, intellectual property, technology development, commercialization, expansion, and future growth. Such statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers should not place undue reliance on forward-looking statements. The company undertakes no obligation to update such statements except as required by law.

This release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities. Any offer or sale of securities will be made only in accordance with the Securities Act of 1933, as amended, and applicable federal and state securities laws.